Cyclo Therapeutics: Rises on positive data on its genetic disorder drug

Cyclo Therapeutics

09/02/2021 15:24

** Shares of drug developer Cyclo Therapeutics Inc  CYTH.O 
soar 20% to $13.46, their highest in more than three months
    ** CYTH presents positive data from its ongoing early-to-mid
stage study of its lead candidate, Trappsol Cyclo, to treat
Niemann-Pick Disease Type C at the 17th Annual WORLD Symposium
2021  urn:newsml:reuters.com:*:nBw7kSDZpa
    ** Says to-date, individual and cumulative safety data show
the drug to be well-tolerated with a favorable safety profile
for all dose groups
    ** Says six of seven patients who completed the trial, as of
September 2020, met the first efficacy criterion of the study
related to improvement in measures of disease severity and
progression 
    ** Co expects to report topline data from study this
quarter; says it has confirmation from regulatory authorities
that the pivotal late-stage study can begin enrollment
    ** Niemann-Pick disease type C is a rare progressive genetic
disorder characterized by an inability of the body to transport
cholesterol and other fatty substances inside of cells
    ** Stock more than doubled YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))